BULARREKO MINBIZIA
Hospital del Mar
Barcelona, EspañaHospital del Mar -ko ikertzaileekin lankidetzan egindako argitalpenak (22)
2024
-
Prevalence of Homologous Recombination Deficiency Among Patients With Germline RAD51C/D Breast or Ovarian Cancer
JAMA network open, Vol. 7, Núm. 4, pp. e247811
2023
-
Long-term outcomes of high-risk HR-positive and HER2-negative early breast cancer patients from GEICAM adjuvant studies and El Álamo IV registry
Breast Cancer Research and Treatment, Vol. 201, Núm. 2, pp. 151-159
-
Reference values of EORTC QLQ-C30, EORTC QLQ-BR23, and EQ-5D-5L for women with non-metastatic breast cancer at diagnosis and 2 years after
Quality of Life Research, Vol. 32, Núm. 4, pp. 989-1003
2022
-
Derived Neutrophil-to-Lymphocyte Ratio Predicts Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer
Frontiers in Oncology, Vol. 11
2020
-
Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients
Cancer Treatment Reviews, Vol. 83
2019
-
Palbociclib and ribociclib in breast cancer: consensus workshop on the management of concomitant medication
Therapeutic Advances in Medical Oncology, Vol. 11
2018
-
Comparing neoadjuvant nab-paclitaxel vs paclitaxel both followed by anthracycline regimens in women with ERBB2/ HER2-negative breast cancer-the evaluating treatment with neoadjuvant abraxane (ETNA) trial a randomized phase 3 clinical trial
JAMA Oncology, Vol. 4, Núm. 3, pp. 302-308
-
The Spanish Society of Cytology: Quality control program of gynecological cytology
Revista Espanola de Patologia, Vol. 51, Núm. 2, pp. 71-76
2016
-
Nab-Paclitaxel in metastatic breast cancer: Defining the best patient profile
Current Cancer Drug Targets, Vol. 16, Núm. 5, pp. 415-428
2015
-
Population-based multicase-control study in common tumors in Spain (MCC-Spain): Rationale and study design
Gaceta Sanitaria, Vol. 29, Núm. 4, pp. 308-315
2014
-
Effect of a diet and physical activity intervention on body weight and nutritional patterns in overweight and obese breast cancer survivors
Medical Oncology, Vol. 31, Núm. 1
-
Treatment innovations for metastatic breast cancer: Nanoparticle albumin-bound (NAB) technology targeted to tumors
Critical Reviews in Oncology/Hematology, Vol. 89, Núm. 1, pp. 62-72
2013
-
Finding the right dose of fulvestrant in breast cancer
Cancer Treatment Reviews, Vol. 39, Núm. 2, pp. 136-141
-
Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: Results from the GEICAM/2003-02 study
Journal of Clinical Oncology
2010
-
Current controversies in the management of breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 4, pp. 278-286
-
Current perspectives of treatment of ductal carcinoma in situ
Cancer Treatment Reviews, Vol. 36, Núm. 7, pp. 507-517
-
Erratum: Current controversies in the management of breast cancer (Clinical and Translational Oncology 12:4 (278-286))
Clinical and Translational Oncology
-
Supportive care for patients with early breast cancer
Clinical and Translational Oncology, Vol. 12, Núm. 1, pp. 32-42
2008
-
Evaluation of international treatment guidelines and prognostic tests for the treatment of early breast cancer
Cancer Treatment Reviews, Vol. 34, Núm. 8, pp. 701-709